Thermo Fisher Scientific and Advanced Electrophoresis Solutions (AES), specialists in protein imaging technologies, have announced an agreement to combine essential protein separation techniques with mass spectrometry (MS) to advance therapeutic protein development through streamlined characterisation.
The companies plan to highlight the strengths of their technologies when coupled for protein analysis to provide laboratories with advanced biopharmaceutical capabilities that will enable insight into results generated by imaged capillary isoelectric focusing (iCIEF) protein separation. This will be of particular benefit to scientists working in the areas of biopharma, clinical, food analysis and academia, the companies say.
"Protein separation, purification and analysis are crucial components in biotherapeutic development, but the process can be complex and challenging," said Eric Grumbach, Director, pharma/biopharma, chromatography and mass spectrometry, Thermo Fisher Scientific. "While mass spectrometry does provide high-sensitivity and high-resolution protein mass information, there are cases where insight from a different angle is required. Through this agreement we will pair our technology with more widely used and essential separation tools previously not routinely coupled to MS to make protein variant identification easier and more accurate to advance high-quality information and scientific knowledge."
Tiemin Huang, CEO, AES, said: "There is a growing demand for proteomics and protein characterization, driven by the rise of personalised medicine, so it’s important that the best combination of tools are available to progress our understanding and research in this important field. By working side-by-side with Thermo Fisher to combine high resolution accurate mass-mass spectrometry (HRAM-MS) with alternative protein separation techniques, we will support our customers to achieve more precise analyses that will play a significant role in the continued development of effective therapeutics."
